Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.13, Iss.4, 2008-12, pp. : 593-607

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

By Deacon Carolyn F Holst Jens J

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2047-2058

Informa Healthcare

Access to resources Recommend Favorite

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes

By Mikhail Nasser

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 845-853

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite

Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment

Current Drug Targets, Vol. 15, Iss. 6, 2014-06 ,pp. : 600-621

Bentham Science Publishers

Access to resources Recommend Favorite

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A Lamos Elizabeth M Davis Stephen N

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite